Approaches to uremia

Journal of the American Society of Nephrology

Volumn 25, Issue 10, 2014, Pages 2151-2158

  Meyer, Timothy W ^a,b   Hostetter, Thomas H ^c  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b STANFORD UNIVERSITY   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

UREA;

HEMODIALYSIS PATIENT; HUMAN; KIDNEY CLEARANCE; KIDNEY FUNCTION; NEPHROTOXICITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; SOLUTE; UREA NITROGEN BLOOD LEVEL; UREMIA; ANIMAL; BLOOD; COMPLICATION; KIDNEY FAILURE, CHRONIC; KIDNEY TUBULE; RENAL REPLACEMENT THERAPY; SECRETION (PROCESS);

ANIMALS; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TUBULES; RENAL DIALYSIS; UREA; UREMIA;

EID: 84921803932     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2013121264     Document Type: Review

References (65)

1. Addis T: Glomerular Nephritis, Diagnosis and Treatment, New York, MacMillan, 1949
2. Schreiner G, Maher J: Biochemistry of uremia. In: Uremia. Springfield, IL, Charles C. Thomas, 1960, pp 55-85.
3. Depner TA: Uremic toxicity: Urea and beyond. Semin Dial 14: 246-251, 2001
4. Duranton F, Cohen G, De Smet R, Rodriguez M, Jankowski J, Vanholder R, Argiles A; European Uremic Toxin Work Group: Normal and pathologic concentrations of uremic toxins. J Am Soc Nephrol 23: 1258-1270, 2012
5. Kimmel PL, Patel SS: Quality of life in patients with chronic kidney disease: Focus on end-stage renal disease treated with hemodialysis. Semin Nephrol 26: 68-79, 2006
6. Perl J, Unruh ML, Chan CT: Sleep disorders in end-stage renal disease: 'Markers of inadequate dialysis'? Kidney Int 70: 1687-1693, 2006
7. Nielens H, Lejeune TM, Lalaoui A, Squifflet JP, Pirson Y, Goffin E: Increase of physical activity level after successful renal transplantation: A 5 year follow-up study. Nephrol Dial Transplant 16: 134-140, 2001
8. Matsumoto N, Ichimura S, Hamaoka T, Osada T, Hattori M, Miyakawa S: Impaired muscle oxygen metabolism in uremic children: Improved after renal transplantation. Am J Kidney Dis 48: 473-480, 2006
9. Harciarek M, Biedunkiewicz B, Lichodziejewska-NiemierkoM, De¸bska-͆lizień A, Rutkowski B: Continuous cognitive improvement 1 year following successful kidney transplant. Kidney Int 79: 1353-1360, 2011
10. Vanholder R, De Smet R, Glorieux G, Argilés A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, Jörres A, Lemke HD, Massy ZA, Passlick-Deetjen J, Rodriguez M, Stegmayr B, Stenvinkel P, Tetta C, Wanner C, Zidek W; European Uremic Toxin Work Group (EUTox): Review on uremic toxins: Classification, concentration, and interindividual variability. Kidney Int 63: 1934-1943, 2003
11. Kikuchi K, Itoh Y, Tateoka R, Ezawa A, Murakami K, Niwa T: Metabolomic analysis of uremic toxins by liquid chromatography/electrospray ionization-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 878: 1662-1668, 2010
12. Toyohara T, Akiyama Y, Suzuki T, Takeuchi Y, Mishima E, Tanemoto M, Momose A, Toki N, Sato H, Nakayama M, Hozawa A, Tsuji I, Ito S, Soga T, Abe T: Metabolomic profiling of uremic solutes in CKD patients. Hypertens Res 33: 944-952, 2010
13. Sato E, Kohno M, Yamamoto M, Fujisawa T, Fujiwara K, Tanaka N: Metabolomic analysis of human plasma from haemodialysis patients. Eur J Clin Invest 41: 241-255, 2011
14. Aronov PA, Luo FJ, Plummer NS, Quan Z, Holmes S, Hostetter TH, Meyer TW: Colonic contribution to uremic solutes. J Am Soc Nephrol 22: 1769-1776, 2011
15. Boelaert J, t'Kindt R, Schepers E, Jorge L, Glorieux G, Neirynck N, Lynen F, Sandra P, Vanholder R, Sandra K: State-of-the-are non-targeted metabolomics in the study of chronic kidney disease. Metabolomics 10: 425-442, 2014
16. Sirich TL, Funk BA, Plummer NS, Hostetter TH, Meyer TW: Prominent accumulation in hemodialysis patients of solutes normally cleared by tubular secretion. J Am Soc Nephrol 25: 615-622, 2014
17. Lowrie EG, Laird NM, Parker TF, Sargent JA: Effect of the hemodialysis prescription of patient morbidity: Report from the National Cooperative Dialysis Study. N Engl J Med 305: 1176-1181, 1981
18. Gotch FA, Sargent JA: A mechanistic analysis of the National Cooperative Dialysis Study (NCDS). Kidney Int 28: 526-534, 1985
19. Schneditz D, Platzer D, Daugirdas JT: A diffusion-adjusted regional blood flow model to predict solute kinetics during haemodialysis. Nephrol Dial Transplant 24: 2218-2224, 2009
20. Itoh Y, Ezawa A, Kikuchi K, Tsuruta Y, Niwa T: Protein-bound uremic toxins in hemodialysis patients measured by liquid chromatography/tandem mass spectrometry and their effects on endothelial ROS production. Anal Bioanal Chem 403: 1841-1850, 2012
21. Rhee EP, Souza A, Farrell L, Pollak MR, Lewis GD, Steele DJ, Thadhani R, Clish CB, Greka A, Gerszten RE: Metabolite profiling identifies markers of uremia. J Am Soc Nephrol 21: 1041-1051, 2010
22. Sirich TL, Aronov PA, Plummer NS, Hostetter TH, Meyer TW: Numerous protein-bound solutes are cleared by the kidney with high efficiency. Kidney Int 84: 585-590, 2013
23. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, Rocco MV, Schulman G, Schwab SJ, Teehan BP, Toto R; Hemodialysis (HEMO) Study Group: Effect of dialysis dose and membrane flux in maintenance hemodialysis. NEngl JMed 347: 2010-2019, 2002
24. Cheung AK, Rocco MV, Yan G, Leypoldt JK, Levin NW, Greene T, Agodoa L, Bailey J, Beck GJ, Clark W, Levey AS, Ornt DB, Schulman G, Schwab S, Teehan B, Eknoyan G: Serumbeta-2 microglobulin levels predict mortality in dialysis patients: Results of the HEMO study. J Am Soc Nephrol 17: 546-555, 2006
25. Ward RA, Greene T, Hartmann B, Samtleben W: Resistance to intercompartmental mass transfer limits beta2-microglobulin removal by post-dilution hemodia filtration. Kidney Int 69: 1431-1437, 2006
26. Evenepoel P, Bammens B, Verbeke K, Vanrenterghem Y: Superior dialytic clearance of beta(2)-microglobulin and p-cresol by high-flux hemodialysis as compared to peritoneal dialysis. Kidney Int 70: 794-799, 2006
27. Pham NM, Recht NS, Hostetter TH, Meyer TW: Removal of the protein-bound solutes indican and p-cresol sulfate by peritoneal dialysis. Clin J Am Soc Nephrol 3: 85-90, 2008
28. Sirich TL, Meyer TW, Gondouin B, Brunet P, Niwa T: Protein-bound molecules: A large family with a bad character. Semin Nephrol 34: 106-117, 2014
29. Want EJ, Nordström A, Morita H, Siuzdak G: From exogenous to endogenous: The inevitable imprint of mass spectrometry in metabolomics. J Proteome Res 6: 459-468, 2007
30. Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, Feldstein AE, Britt EB, Fu X, Chung YM, Wu Y, Schauer P, Smith JD, Allayee H, Tang WH, DiDonato JA, Lusis AJ, Hazen SL: Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472: 57-63, 2011
31. Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, McCabe E, Lewis GD, Fox CS, Jacques PF, Fernandez C, O'Donnell CJ, Carr SA, Mootha VK, Florez JC, Souza A, Melander O, Clish CB, Gerszten RE: Metabolite profiles and the risk of developing diabetes. Nat Med 17: 448-453, 2011
32. Grooteman MP, van den Dorpel MA, Bots ML, Penne EL, van der Weerd NC, Mazairac AH, den Hoedt CH, van der Tweel I, Lévesque R, Nubé MJ, ter Wee PM, Blankestijn PJ; CONTRAST Investigators: Effect of online hemodiafiltration on all-cause mortality and cardiovascular outcomes. J Am Soc Nephrol 23: 1087-1096, 2012
33. Maduell F, Moreso F, Pons M, Ramos R, Mora-Macià J, Carreras J, Soler J, Torres F, Campistol JM, Martinez-Castelao A; ESHOL Study Group: High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients. J Am Soc Nephrol 24: 487-497, 2013
34. Locatelli F, Martin-Malo A, Hannedouche T, Loureiro A, Papadimitriou M, Wizemann V, Jacobson SH, Czekalski S, Ronco C, Vanholder R; Membrane Permeability Outcome (MPO) Study Group: Effect of membrane permeability on survival of hemodialysis patients. J Am Soc Nephrol 20: 645-654, 2009
35. Ok E, Asci G, Toz H, Ok ES, Kircelli F, Yilmaz M, Hur E, Demirci MS, Demirci C, Duman S, Basci A, Adam SM, Isik IO, Zengin M, Suleymanlar G, Yilmaz ME, Ozkahya M: Mortality and cardiovascular events in online haemodiafiltration (OL-HDF) compared with high-flux dialysis: Results from the Turkish OL-HDF Study. Nephrol Dial Transplant 28: 192-202, 2013
36. Luo FJ, Patel KP, Marquez IO, Plummer NS, Hostetter TH, Meyer TW: Effect of increasing dialyzer mass transfer area coefficient and dialysate flow on clearance of protein-bound solutes: a pilot crossover trial. Am J Kidney Dis 53: 1042-1049, 2009
37. Sirich TL, Luo FJ, Plummer NS, Hostetter TH, Meyer TW: Selectively increasing the clearance of protein-bound uremic solutes. Nephrol Dial Transplant 27: 1574-1579, 2012
38. Paniagua R, Amato D, Vonesh E, Correa-Rotter R, Ramos A, Moran J, Mujais S; Mexican Nephrology Collaborative Study Group: Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 13: 1307-1320, 2002
39. Evenepoel P, Meijers BK, Bammens BR, Verbeke K: Uremic toxins originating from colonic microbial metabolism. Kidney Int Suppl S12-S19, 2009
40. Schepers E, Glorieux G, Vanholder R: The gut: The forgotten organ in uremia? Blood Purif 29: 130-136, 2010
41. Meyer TW, Hostetter TH: Uremic solutes from colon microbes. Kidney Int 81: 949-954, 2012
42. Niwa T, Emoto Y, Maeda K, Uehara Y, Yamada N, Shibata M: Oral sorbent suppresses accumulation of albumin-bound indoxyl sulphate in serum of haemodialysis patients. Nephrol Dial Transplant 6: 105-109, 1991
43. Meijers BK, De Preter V, Verbeke K, Vanrenterghem Y, Evenepoel P: p-Cresyl sulfate serum concentrations in haemodialysis patients are reduced by the prebiotic oligofructose-enriched inulin. Nephrol Dial Transplant 25: 219-224, 2010
44. Bargman JM: Is there more to living than not dying? A reflection on survival studies in dialysis. Semin Dial 20: 50-52, 2007
45. Müting D: Studies on the pathogenesis of uremia. Comparative determinations of glucuronic acid, indican, free and bound phenols in the serum, cerebrospinal fluid, and urine of renal diseases with and without uremia. Clin Chim Acta 12: 551-554, 1965
46. Porter RD, Cathcart-Rake WF, Wan SH, Whittier FC, Grantham JJ: Secretory activity and aryl acid content of serum, urine, and cerebrospinal fluid in normal and uremic man. J Lab Clin Med 85: 723-731, 1975
47. Spector R, Snodgrass SR: The effect of uremia on penicillin flux between blood and cerebrospinal fluid. J Lab Clin Med 87: 749-759, 1976
48. Deguchi T, Isozaki K, Yousuke K, Terasaki T, Otagiri M: Involvement of organic anion transporters in the efflux of uremic toxins across the blood-brain barrier. J Neurochem 96: 1051-1059, 2006
49. Hosoya KI, Tachikawa M: Roles of organic anion/cation transporters at the blood-brain and blood-cerebrospinal fluid barriers involving uremic toxins. Clin Exp Nephrol 15: 478-485, 2011
50. Lieberman HR: Cognitive methods for assessing mental energy. Nutr Neurosci 10: 229-242, 2007
51. Teschan PE: Electroencephalographic and other neurophysiological abnormalities in uremia. Kidney Int Suppl 210-216, 1975
52. Kurella Tamura M, Yaffe K: Dementia and cognitive impairment in ESRD: Diagnostic and therapeutic strategies. Kidney Int 79: 14-22, 2011
53. Madero M, Gul A, Sarnak MJ: Cognitive function in chronic kidney disease. Semin Dial 21: 29-37, 2008
54. Blake C, O'Meara YM: Subjective and objective physical limitations in high-functioning renal dialysis patients. Nephrol Dial Transplant 19: 3124-3129, 2004
55. Himmelfarb J: Uremic toxicity, oxidative stress, and hemodialysis as renal replacement therapy. Semin Dial 22: 636-643, 2009
56. Himmelfarb J, McMonagle E, McMenamin E: Plasma protein thiol oxidation and carbonyl formation in chronic renal failure. Kidney Int 58: 2571-2578, 2000
57. Marshall EK Jr: Two lectures on renal physiology. Physiologist 9: 367-384, 1966
58. Singer MA, Morton AR: Mouse to elephant: Biological scaling and Kt/V. Am J Kidney Dis 35: 306-309, 2000
59. Beuchat CA: Structure and concentrating ability of the mammalian kidney: Correlations with habitat. Am J Physiol 271: R157-R179, 1996
60. Anzai N, Kanai Y, Endou H: Organic anion transporter family: Current knowledge. J Pharmacol Sci 100: 411-426, 2006
61. Wikoff WR, Nagle MA, Kouznetsova VL, Tsigelny IF, Nigam SK: Untargeted metabolomics identifies enterobiome metabolites and putative uremic toxins as substrates of organic anion transporter 1 (Oat1). J Proteome Res 10: 2842-2851, 2011
62. Fine L: The biology of renal hypertrophy. Kidney Int 29: 619-634, 1986
63. Wesson LG: Compensatory growth and other growth responses of the kidney. Nephron 51: 149-184, 1989
64. Hayslett JP: Functional adaptation to reduction in renal mass. Physiol Rev 59: 137-164, 1979
65. Meyer TW, Sirich TL, Hostetter TH: Dialysis cannot bedosed. Semin Dial 24: 471-479, 2011